Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SANA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSana Biotechnology reclassifies director to rebalance board classes
Filed April 24, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
low
Dr. Steven D. Harr moved from Class I to Class III director on April 22, 2026, changing his term expiration from 2028 to 2027. The technical reclassification rebalances the board so each of three classes now has three directors.
Item 5.02 verify on EDGAR → -
low
The reclassification was done solely to comply with the company's certificate of incorporation requirements. Dr. Harr's service is deemed continuous with no interruption.
8-K: Director Change view on EDGAR →
Summary
Sana Biotechnology filed a routine compliance disclosure announcing a technical reclassification of board member Dr. Steven D. Harr. On April 22, 2026, Dr. Harr resigned as a Class I director and was immediately re-appointed as a Class III director.
This administrative change shifts his term expiration from 2028 to 2027 and rebalances the company's staggered board structure so that each of the three classes now contains three directors, as required by the company's certificate of incorporation. For retail investors, this filing has no material impact on the company's operations, strategy, or governance. Dr.
Harr remains on the board with continuous service, and the change is purely procedural to maintain proper board class balance. No action is required, and shareholders can expect normal board operations to continue unchanged.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify